These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16916701)

  • 1. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer.
    Pickles MD; Gibbs P; Lowry M; Turnbull LW
    Magn Reson Imaging; 2006 Sep; 24(7):843-7. PubMed ID: 16916701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Sharma U; Danishad KK; Seenu V; Jagannathan NR
    NMR Biomed; 2009 Jan; 22(1):104-13. PubMed ID: 18384182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.
    Buijs M; Kamel IR; Vossen JA; Georgiades CS; Hong K; Geschwind JF
    J Vasc Interv Radiol; 2007 Aug; 18(8):957-63. PubMed ID: 17675611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.
    Yu HJ; Chen JH; Mehta RS; Nalcioglu O; Su MY
    J Magn Reson Imaging; 2007 Sep; 26(3):615-23. PubMed ID: 17729334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
    Rhee TK; Naik NK; Deng J; Atassi B; Mulcahy MF; Kulik LM; Ryu RK; Miller FH; Larson AC; Salem R; Omary RA
    J Vasc Interv Radiol; 2008 Aug; 19(8):1180-6. PubMed ID: 18656011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study.
    Chou CP; Wu MT; Chang HT; Lo YS; Pan HB; Degani H; Furman-Haran E
    Acad Radiol; 2007 May; 14(5):561-73. PubMed ID: 17434070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
    Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
    Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas.
    Dudeck O; Zeile M; Pink D; Pech M; Tunn PU; Reichardt P; Ludwig WD; Hamm B
    J Magn Reson Imaging; 2008 May; 27(5):1109-13. PubMed ID: 18425832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
    Kim SJ; Taguchi T; Shimazu K; Tanji Y; Tamaki Y; Noguchi S
    Oncology; 2009; 77(2):134-9. PubMed ID: 19628951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
    Végran F; Boidot R; Oudin C; Riedinger JM; Bonnetain F; Lizard-Nacol S
    Clin Cancer Res; 2006 Oct; 12(19):5794-800. PubMed ID: 17020986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.